These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35849446)

  • 1. Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout.
    Kamel B; Abuhelwa AY; Foster D; Duong JK; Graham GG; Williams KM; Pile KD; Day RO
    Br J Clin Pharmacol; 2022 Dec; 88(12):5359-5368. PubMed ID: 35849446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.
    Kamel B; Graham GG; Williams KM; Pile KD; Day RO
    Clin Pharmacokinet; 2017 May; 56(5):459-475. PubMed ID: 27753003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
    Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
    Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.
    Rekić D; Johansson S; Leander J
    Clin Pharmacokinet; 2021 Mar; 60(3):319-328. PubMed ID: 32951150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.
    Kamel B; Graham GG; Stocker SL; Liu Z; Williams KM; Carland JE; Pile KD; Day RO
    Br J Clin Pharmacol; 2020 Dec; 86(12):2486-2496. PubMed ID: 32386239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
    Tan B; Naik H; Jang IJ; Yu KS; Kirsch LE; Shin CS; Craft JC; Fleckenstein L
    Malar J; 2009 Dec; 8():304. PubMed ID: 20021657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of axitinib in healthy volunteers.
    Garrett M; Poland B; Brennan M; Hee B; Pithavala YK; Amantea MA
    Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers.
    Xue L; Zhang H; Ma S; Rui JZ; Miao LY
    Pharmacology; 2011; 88(5-6):288-94. PubMed ID: 22075549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment.
    Hira D; Chisaki Y; Noda S; Araki H; Uzu T; Maegawa H; Yano Y; Morita SY; Terada T
    Pharmacology; 2015; 96(1-2):90-8. PubMed ID: 26183164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling.
    Xu Y; Chen J; Ruan Z; Jiang B; Yang D; Hu Y; Lou H
    Biopharm Drug Dispos; 2022 Aug; 43(4):140-151. PubMed ID: 35748093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):587-594. PubMed ID: 28247011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus
.
    Zang YN; Zhang MJ; Wang YT; Wang C; Wang Q; Zheng QS; Ji LN; Guo W; Fang Y
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):650-658. PubMed ID: 28513427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation.
    Wei Y; Wu D; Chen Y; Dong C; Qi J; Wu Y; Cai R; Zhou S; Li C; Niu L; Wu T; Xiao Y; Liu T
    Front Pharmacol; 2022; 13():1002628. PubMed ID: 36313303
    [No Abstract]   [Full Text] [Related]  

  • 16. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.
    Godfrey C; Sweeney K; Miller K; Hamilton R; Kremer J
    Br J Clin Pharmacol; 1998 Oct; 46(4):369-76. PubMed ID: 9803986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
    Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
    Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C
    Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.